Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437624 | 0.91 | PTPRC (0.43) | DGAT2MAPTLRRK2CA1CA2 | |
| SCHEMBL6436909 | 0.85 | DGAT2 (0.50) | DGAT2MAPTSMN1; SMN2CSNK2A2CLK2 | |
| SCHEMBL6436503 | 0.85 | CA1 (0.48) | SMN1; SMN2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL6436986 | 0.82 | ROCK2 (0.34) | DGAT2MAPTLRRK2CA1CA2 | |
| SCHEMBL6433070 | 0.81 | PLAU (0.52) | MAPTSMN1; SMN2PLAU | |
| SCHEMBL6433233 | 0.80 | ROCK2 (0.41) | — | |
| SCHEMBL6432919 | 0.79 | CA1 (0.39) | DGAT2MAPTSMN1; SMN2LRRK2CA1 | |
| SCHEMBL7367423 | 0.79 | POLB (0.46) | MAPT | |
| SCHEMBL6432702 | 0.78 | GRN (0.41) | MAPTLRRK2CA1CA2STAT3 | |
| SCHEMBL6434410 | 0.78 | MAPT (0.45) | MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | DGAT2 2226/4885MAPT 2392/4885SMN1; SMN2 2612/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | DGAT2 2226/4885MAPT 2392/4885SMN1; SMN2 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.